Holen Sie sich die Stockscreener-App
3.71
5.64%
-0.28
Incannex Healthcare Inc Aktie (IXHL) Neueste Nachrichten
Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025. - marketscreener.com
Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 – DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
IXHL Forecast — Price Target — Prediction for 2027 - TradingView
Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality - Manufacturing Chemist
Incannex Healthcare Inc. Actuals & Estimates (NASDAQ:IXHL) - TradingView
Incannex Healthcare Inc (IXHL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why Did IXHL Stock Tank Over 32% Today? - Stocktwits
A2DF4D Forecast — Price Target — Prediction for 2027 - TradingView
Incannex receives U.S. patent for sleep apnea drug IHL-42X - Investing.com
Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea - marketscreener.com
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea - The Manila Times
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Incannex's sleep apnea drug gets U.S. patent protection to 2040 - Stock Titan
Incannex (IXHL) secures long-dated U.S. patent for IHL-42X sleep apnoea therapy - Stock Titan
Incannex Healthcare Inc (IXHL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incannex Healthcare Inc (IXHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Is Incannex (ASX:IHL) Emerging as a Clinical Cannabis Story? - Kalkine Media
IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
Incannex Healthcare Inc (IXHL) Institutional Confidence - TradingKey
Incannex Healthcare Inc (IXHL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Incannex Healthcare (IXHL) Proxy Filing Summary - Quartr
Incannex Healthcare receives A$6m R&D tax incentive payment By Investing.com - Investing.com Nigeria
IXHL Stock Gains As Incannex Reactivates Share Repurchase Program - Stocktwits
IXHL Should I Buy - Intellectia AI
Incannex Healthcare Inc (IXHL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incannex Healthcare Inc (IXHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Incannex Healthcare Inc (IXHL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex Healthcare receives A$6m R&D tax incentive payment - Investing.com UK
Incannex Healthcare Secures Major Non-Dilutive R&D Funding - TipRanks
Incannex Healthcare Secures Over A$11 Million in Non-Dilutive Capital Through Australian R&D Tax Incentive Program - Quiver Quantitative
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility - The Manila Times
Incannex lines up A$11m in non‑dilutive cash to advance IHL‑42X study - Stock Titan
Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding - TradingView
Incannex (Nasdaq: IXHL) secures over A$11.1M in R&D tax incentives - Stock Titan
Incannex Healthcare: Target Price Consensus and Analysts Recommendations | IQI | AU000000IHL8 - marketscreener.com
Incannex Healthcare Gains Independent Buy-Rated Research Coverage - TipRanks
Sleep apnea and anxiety drug developer Incannex gets AGP buy rating at $18 - Stock Titan
Incannex Healthcare: Alliance Global Partners Starts Coverage with $18 Price Target - TradingView
Alliance Global initiates Incannex (IXHL) equity research coverage on key drug pipeline - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
$Incannex Healthcare (IXHL.US)$ [Onlooker][OK] - Moomoo
INCANNEX HEALTHCARE INC (IXHL) Stock Chart - ChartMill
Incannex Healthcare Q1 2026 Earnings: Deep EPS Miss Reflects Heavy R&D InvestmentOperating Income Trends - newsline.com
Why Are ASX Cannabis Stocks Drawing Fresh Attention? - Kalkine Media
0.67%
1.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):